ALNYLAM PHARMACEUTICALS, INC. Sale of Stock, Consideration Received Per Transaction
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Sale of Stock, Consideration Received Per Transaction of $10.00 million for the 1-month period ending 2009-03-31, per its 10-K filed 2015-02-13.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedPerTransaction · last filed 2015-02-13
- 2009-03-31: Sale of Stock, Consideration Received Per Transaction 1 month $10.00M.
| Period end | Sale of Stock, Consideration Received Per Transaction 1 month |
|---|---|
| 2009-03-31 | $10.00M 10-K · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |